Jones Trading维持WAVE Life Sciences (NASDAQ:WVE)的买入评级和12.00美元的目标价。该公司的立场是在WAVE Life Sciences发布了其杜氏肌营养不良症(DMD)治疗的六个月中期dystrophin数据之后做出的。这种治疗旨在跳过Exon 53。数据显示平均dystrophin表达为5.5%,范围在3.3%至8.3%之间。 这一表现与NS Pha ...
Before jumping into retail journalism in January 2024, Pola worked for Times Higher Education, where she was was Asia reporter and co-editor of THE’s global university rankings supplement – a gig that ...
Here, KDDF presents its ADCaptain project to fuel the development of next-generation antibody–drug conjugate therapies, and four of the Korean company ... is developing LEM-S403, a novel ...